Japan considering intradermal seasonal influenza vaccine

Japan Vaccine Co., Ltd., which is affiliated with Daiichi Sankyo, Inc., recently submitted an application to manufacture and sell a pre-filled syringe type intradermal seasonal influenza HA vaccine in Japan.

Four companies developed the vaccine: Daiichi Sankyo; Kitasato Daiichi Sankyo Vaccine Co., Ltd.; Terumo; and Japan Vaccine. This collaboration was made as part of an agreement between Terumo and Daiichi Sankyo.

Terumo was responsible for creating the intradermal injection device, which makes it easier to administer the vaccine. This new method should ease patients' fear about receiving  injected vaccines since it isn't as deep as vaccines administered to the hypodermis. The new device also lessens the chances of damaging peripheral blood vessels or nerves as the health care worker injects the vaccine into the subcutaneous tissue.

Daiichi Sankyo executives have voiced their commitment to further developments that will prevent the spread of seasonal influenza. They see the new vaccine as one of the best ways to achieve this goal.  Daiichi also seeks to improve hygiene as the company continues to contribute to the vaccine industry.

Organizations in this Story

Daiichi Sankyo, Inc.

Want to get notified whenever we write about Daiichi Sankyo, Inc. ?
Next time we write about Daiichi Sankyo, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.